1.73
+0(+0.00%)
Currency In USD
Address
2155 Park Boulevard
Palo Alto, CA 94306
United States of America
Phone
650 272 6138
Website
Sector
Healthcare
Industry
Biotechnology
Employees
56
First IPO Date
January 30, 2014
| Name | Title | Pay | Year Born |
| Dr. David Apelian M.B.A., M.D., Ph.D. | Chief Executive Officer & Director | 204,386 | 1965 |
| Dr. Jeffrey S. Glenn M.D., Ph.D. | Scientific Founder & Independent Director | 67,000 | 1963 |
| Mr. William G. Kaichoff CPA | Chief Financial Officer and Principal Financial & Accounting Officer | 0 | 1966 |
| Dr. Colin Hislop M.D., MBBS | Senior Vice President of Clinical & Development Operations | 0 | 1958 |
| Mr. James Vollins J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary | 0 | 1969 |
| Dr. Colleen Craig M.D. | Senior Vice President of Metabolic Diseases | 0 | N/A |
| Mr. Christopher A. Kurtz | Chief Technical Officer | 0 | 1967 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.